Cargando…
Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study
OBJECTIVES: Persistence with an antiretroviral therapy (ART) regimen for HIV can be defined as the length of time a patient remains on therapy before stopping or switching. We aimed to describe ART persistence in treatment naïve patients starting therapy in the United Kingdom, and to describe differ...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
W.B. Saunders
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346156/ https://www.ncbi.nlm.nih.gov/pubmed/28143756 http://dx.doi.org/10.1016/j.jinf.2017.01.012 |
_version_ | 1782513834774233088 |
---|---|
author | Lewis, Joseph M. Smith, Colette Torkington, Adele Davies, Craig Ahmad, Shazaad Tomkins, Andrew Shaw, Jonathan Kingston, Margaret Muqbill, Ghadeer Hay, Philip Mulka, Larissa Williams, Deborah Waters, Laura Brima, Nataliya Marshall, Neal Johnson, Margaret Chaponda, Mas Nelson, Mark |
author_facet | Lewis, Joseph M. Smith, Colette Torkington, Adele Davies, Craig Ahmad, Shazaad Tomkins, Andrew Shaw, Jonathan Kingston, Margaret Muqbill, Ghadeer Hay, Philip Mulka, Larissa Williams, Deborah Waters, Laura Brima, Nataliya Marshall, Neal Johnson, Margaret Chaponda, Mas Nelson, Mark |
author_sort | Lewis, Joseph M. |
collection | PubMed |
description | OBJECTIVES: Persistence with an antiretroviral therapy (ART) regimen for HIV can be defined as the length of time a patient remains on therapy before stopping or switching. We aimed to describe ART persistence in treatment naïve patients starting therapy in the United Kingdom, and to describe differential persistence by treatment regimen. METHODS: We performed a retrospective cohort study at eight UK centres of ART-naïve adults commencing ART between 2012 and 2015. Aggregate data were extracted from local treatment databases. Time to discontinuation was compared for different third agents and NRTI backbones using incidence rates. RESULTS: 1949 patients contributed data to the analysis. Rate of third agent change was 28 per 100 person-years of follow up [95% CI 26–31] and NRTI backbone change of 15 per 100 person-years of follow up [95% CI 14–17]). Rilpivirine, as co-formulated rilpivirine/tenofovir/emtricitabine had a significantly lower discontinuation rate than all other third agents and, excluding single tablet regimens, co-formulated tenofovir/emtricitabine had a significantly lower discontinuation rate than co-formulated abacavir/lamivudine. The reasons for discontinuation were not well recorded. CONCLUSIONS: Treatment discontinuation is not an uncommon event. Rilpivirine had a significantly lower discontinuation rate than other third agents and tenofovir/emtricitabine a lower rate than co-formulated abacavir/lamivudine. |
format | Online Article Text |
id | pubmed-5346156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | W.B. Saunders |
record_format | MEDLINE/PubMed |
spelling | pubmed-53461562017-04-01 Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study Lewis, Joseph M. Smith, Colette Torkington, Adele Davies, Craig Ahmad, Shazaad Tomkins, Andrew Shaw, Jonathan Kingston, Margaret Muqbill, Ghadeer Hay, Philip Mulka, Larissa Williams, Deborah Waters, Laura Brima, Nataliya Marshall, Neal Johnson, Margaret Chaponda, Mas Nelson, Mark J Infect Article OBJECTIVES: Persistence with an antiretroviral therapy (ART) regimen for HIV can be defined as the length of time a patient remains on therapy before stopping or switching. We aimed to describe ART persistence in treatment naïve patients starting therapy in the United Kingdom, and to describe differential persistence by treatment regimen. METHODS: We performed a retrospective cohort study at eight UK centres of ART-naïve adults commencing ART between 2012 and 2015. Aggregate data were extracted from local treatment databases. Time to discontinuation was compared for different third agents and NRTI backbones using incidence rates. RESULTS: 1949 patients contributed data to the analysis. Rate of third agent change was 28 per 100 person-years of follow up [95% CI 26–31] and NRTI backbone change of 15 per 100 person-years of follow up [95% CI 14–17]). Rilpivirine, as co-formulated rilpivirine/tenofovir/emtricitabine had a significantly lower discontinuation rate than all other third agents and, excluding single tablet regimens, co-formulated tenofovir/emtricitabine had a significantly lower discontinuation rate than co-formulated abacavir/lamivudine. The reasons for discontinuation were not well recorded. CONCLUSIONS: Treatment discontinuation is not an uncommon event. Rilpivirine had a significantly lower discontinuation rate than other third agents and tenofovir/emtricitabine a lower rate than co-formulated abacavir/lamivudine. W.B. Saunders 2017-04 /pmc/articles/PMC5346156/ /pubmed/28143756 http://dx.doi.org/10.1016/j.jinf.2017.01.012 Text en © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lewis, Joseph M. Smith, Colette Torkington, Adele Davies, Craig Ahmad, Shazaad Tomkins, Andrew Shaw, Jonathan Kingston, Margaret Muqbill, Ghadeer Hay, Philip Mulka, Larissa Williams, Deborah Waters, Laura Brima, Nataliya Marshall, Neal Johnson, Margaret Chaponda, Mas Nelson, Mark Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study |
title | Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study |
title_full | Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study |
title_fullStr | Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study |
title_full_unstemmed | Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study |
title_short | Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study |
title_sort | real-world persistence with antiretroviral therapy for hiv in the united kingdom: a multicentre retrospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346156/ https://www.ncbi.nlm.nih.gov/pubmed/28143756 http://dx.doi.org/10.1016/j.jinf.2017.01.012 |
work_keys_str_mv | AT lewisjosephm realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT smithcolette realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT torkingtonadele realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT daviescraig realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT ahmadshazaad realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT tomkinsandrew realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT shawjonathan realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT kingstonmargaret realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT muqbillghadeer realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT hayphilip realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT mulkalarissa realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT williamsdeborah realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT waterslaura realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT brimanataliya realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT marshallneal realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT johnsonmargaret realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT chapondamas realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy AT nelsonmark realworldpersistencewithantiretroviraltherapyforhivintheunitedkingdomamulticentreretrospectivecohortstudy |